Literature DB >> 2775696

Oral contraceptive steroids and breast secretions.

W R Miller1, R A Elton, N Loudon.   

Abstract

Breast secretions were obtained by nipple aspiration from 164 (44.7%) of 368 consecutive premenopausal non-pregnant women volunteers attending family planning clinics. Women currently taking oral contraceptive steroids were significantly less likely to yield breast secretions than women who had never taken such preparations. The effect was confined to parous women of whom 94% not taking oral contraceptives yielded breast secretions compared with only 51% currently using the pill and 60% of those with a previous history of use. The percentage of nulliparous women yielding breast secretions (30%) was significantly less than that in parous women and was not affected by a present or previous history of contraceptive steroid use. These results provide further evidence of the difference in hormone responsiveness of parous and nulliparous breasts and the potential of oral contraceptive steroids to influence breast function.

Entities:  

Keywords:  Biology; Contraception; Contraceptive Methods--side effects; Correlation Studies; Demographic Factors; Family Planning; Fertility; Fertility Measurements; Mammary Gland Effects; Oral Contraceptives--side effects; Parity; Physiology; Population; Population Dynamics; Research Methodology; Statistical Studies; Studies

Mesh:

Substances:

Year:  1989        PMID: 2775696     DOI: 10.1111/j.1471-0528.1989.tb03356.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  2 in total

1.  Dietary intake of lactose as a strong predictor for secretor status of nipple aspirate fluid in healthy premenopausal nonlactating women.

Authors:  Yafei Huang; Karl E Anderson; Manubai Nagamani; James J Grady; Lee-Jane W Lu
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

2.  Factors affecting protein composition of breast secretions from nonlactating women.

Authors:  F Vizoso; L M Sánchez; I Díez-Itza; M Luz Lamelas; C López-Otín
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.